title: Efavirenz concentrations in HIV-infected patients with and without viral hepatitis.
abstract: OBJECTIVE
  Data on efavirenz in HIV/viral hepatitis co-infected patients is non-consensual, probably due to liver function heterogeneity in the patients included.
  
  
  METHODS
  A case control study was performed on 27 HIV-infected patients, with controlled and homogenous markers of hepatic function, either mono-infected or co-infected with HBV/HCV, to ascertain the influence of viral hepatitis on efavirenz concentrations over a 2-year follow-up period.
  
  
  RESULTS
  No differences were found in efavirenz concentrations between groups both during and at the end of the follow-up period: control (2.43 +/- 1.91 mg l(-1)) vs. co-infected individuals (2.37 +/- 0.37 mg l(-1)).
  
  
  CONCLUSIONS
  It was concluded that HBV/HCV infections in themselves do not predispose to an overexposure to efavirenz.
authors.affiliation: Department of Pharmacology, Faculty of Medical Sciences, New University of Lisbon, Lisbon, Portugal.
authors.forename: Sofia A
authors.initials: SA
authors.lastname: Pereira
authors.forename: Umbelina
authors.initials: U
authors.lastname: Caixas
authors.forename: Teresa
authors.initials: T
authors.lastname: Branco
authors.forename: Isabel
authors.initials: I
authors.lastname: Germano
authors.forename: Fátima
authors.initials: F
authors.lastname: Lampreia
authors.forename: Ana L
authors.initials: AL
authors.lastname: Papoila
authors.forename: Emília C
authors.initials: EC
authors.lastname: Monteiro
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy; D000328:Adult; D000480:Alkynes; D048588:Benzoxazines / Q000493:pharmacokinetics / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D016022:Case-Control Studies; D003521:Cyclopropanes; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D016903:Drug Monitoring; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000188:drug therapy* / Q000378:metabolism; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000378:metabolism; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D008107:Liver Diseases / Q000150:complications / Q000188:drug therapy; D008297:Male; D010865:Pilot Projects; D018894:Reverse Transcriptase Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use*; D012720:Severity of Illness Index; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D000480:Alkynes; D048588:Benzoxazines; D003521:Cyclopropanes; D018894:Reverse Transcriptase Inhibitors; C098320:efavirenz